RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

著者: Diya Surie, Wesley H. Self, Yuwei Zhu, Katharine A. Yuengling, Cassandra A. Johnson, Carlos G. Grijalva, Fatimah S. Dawood, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Manjusha Gaglani, Shekhar Ghamande, Tresa McNeal, Cristie Columbus, Robert Gottlieb, Jay S. Steingrub, Jennifer DeCuir, Meredith McMorrow, Sascha Ellington, Nathaniel M. Lewis, Abhijit Duggal, Laurence W. Busse, William S. Bender, Matthew E. Prekker, Anne Frosch, Ithan D. Peltan, Samuel M. Brown, David N. Hager, Michelle N. Gong, Amira Mohamed, Akram Khan, Catherine L. Hough, Jennifer G. Wilson, Jarrod Mosier, Nida Qadir, Steven Y. Chang, Adit A. Ginde, Nicholas M. Mohr, Anne Zepeski, Christopher Mallow, Adam S. Lauring, Emily T. Martin, Aleda M. Leis, Estelle S. Harris, Nicholas J. Johnson, Vasisht Srinivasan, H. Keipp Talbot, Natasha Halasa, James D. Chappell, Kelsey N. Womack, Jillian P. Rhoads, Adrienne Baughman, Sydney A. Swan, Todd W. Rice, Jonathan D. Casey, Paul W. Blair, Kevin W. Gibbs, Jennie H. Kwon, Bijal A. Parikh, Ivana A. Vaughn, Mayur Ramesh, Basmah Safdar - JAMA 2024 被引用: 66

This study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older.